{
    "nct_id": "NCT06128629",
    "official_title": "MAGNITUDE: a Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)",
    "inclusion_criteria": "* Documented diagnosis of ATTR amyloidosis with cardiomyopathy\n* Medical history of heart failure (HF)\n* Symptoms of HF are optimally managed and clinically stable within 28 days prior to administration of study intervention\n* Screening NT-proBNP, a blood marker of HF severity, greater than or equal to 600 pg/mL and less than 10,000 pg/mL\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 90 Years",
    "exclusion_criteria": "* New York Heart Association (NYHA) Class IV HF\n* Polyneuropathy Disability score of IV (confined to wheelchair or bed)\n* Has hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection\n* History of active malignancy within 3 years prior to screening\n* RNA silencer therapy (patisiran, inotersen and/or eplontersen) within 12 months prior to dosing. Any prior vutrisiran use is not allowed\n* Initiation of tafamidis or acoramidis within 56 days prior to study dosing\n* Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m^2\n* Liver failure\n* Uncontrolled blood pressure\n* Unable or unwilling to take vitamin A supplementation for the duration of the study",
    "miscellaneous_criteria": ""
}